Clinical trial
Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736…
NCT03287414 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT03287414 |
|---|---|
| Title | Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis |
| Official title | A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Idiopathic Pulmonary Fibrosis |
| Intervention type | Drug |
| Interventions | VAY736, Placebo, Standard of Care (SoC) |
| Enrollment | 30 |
| Start date | Dec 20, 2017 |
| Primary completion | Nov 25, 2020 |
| Completion | Feb 14, 2022 |
| First posted | Sep 19, 2017 |
| Last update posted | Jun 18, 2024 |
| Countries | Canada, Germany, Ireland, Italy, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: